Abstract: The present disclosure provides an intraoral fast disintegrating formulation containing hemp oil extract or hemp powder extract as a raw material of the formulation, wherein the formulation contains a water-soluble binder, an inorganic material and a surfactant.

Abstract: Disclosed is a capsule filling apparatus. The capsule filling apparatus includes a supplying member configured to supply a tablet; a moving member configured to move the tablet supplied from the supplying member in a preset direction; a catching member configured to catch the tablet moved by the moving member by suction and insert the caught tablet into a capsule; and a capsule accommodating member located below the catching member so that the capsule is accommodated therein.

Abstract: The present disclosure relates to an orally administered pharmaceutical formulation containing an inclusion complex formed as varenicline or a pharmaceutically acceptable salt thereof is included in cyclodextrin. The pharmaceutical formulation can improve convenience of medication by effectively masking the bitter taste of the drug and the irritation during swallowing, can provide the oxidation stability of varenicline and can improve the solubility of the drug.

Abstract: The present disclosure relates to a film formulation for oral administration, containing tadalafil free base and a method of preparing the same, and a film may be provided with maximized dispersion stability of tadalafil free base in the film by the addition of a dispersion stabilizing agent in small amounts without unique fragrance or favor that may appear when other dispersion stabilizing agents known in the art are used, and an extremely low likelihood that a reagglomeration phenomenon of tadalafil free base particles will occur, and an amount of bubbles generated may be significantly reduced during a production process.

Abstract: Disclosed is a capsule filling apparatus. The capsule filling apparatus includes a supplying member configured to supply a tablet; a moving member configured to move the tablet supplied from the supplying member in a preset direction; an adsorbing member configured to adsorb the tablet moved by the moving member and insert the adsorbed tablet into a capsule; and a capsule accommodating member located below the adsorbing member so that the capsule is accommodated therein.

Abstract: The present disclosure relates to a film formulation for oral administration, containing tadalafil free base and a method of preparing the same, and a film may be provided with maximized dispersion stability of tadalafil free base in the film by the addition of a dispersion stabilizing agent in small amounts without unique fragrance or favor that may appear when other dispersion stabilizing agents known in the art are used, and an extremely low likelihood that a reagglomeration phenomenon of tadalafil free base particles will occur, and an amount of bubbles generated may be significantly reduced during a production process.

Abstract: The present disclosure relates to a pharmaceutical preparation having varenicline or a pharmaceutically acceptable salt thereof as an active ingredient. More particularly, it relates to an orally administered pharmaceutical preparation which allows limited use of a sweetening agent or a flavoring agent by effectively masking the unique taste of varenicline, particularly bitterness, which is a bitter and burning taste, and ensures convenience in taking the pharmaceutical preparation by being orally administrable without irritation, while containing a pharmaceutically effective amount of varenicline or a pharmaceutically acceptable salt thereof, and a method for preparing the same.

Abstract: The present disclosure relates to a film formulation for oral administration, containing tadalafil free base and a method of preparing the same, and a film may be provided with maximized dispersion stability of tadalafil free base in the film by the addition of a dispersion stabilizing agent in small amounts without unique fragrance or favor that may appear when other dispersion stabilizing agents known in the art are used, and an extremely low likelihood that a reagglomeration phenomenon of tadalafil free base particles will occur, and an amount of bubbles generated may be significantly reduced during a production process.

Abstract: The present disclosure relates to an orally administered pharmaceutical formulation containing an inclusion complex formed as varenicline or a pharmaceutically acceptable salt thereof is included in cyclodextrin. The pharmaceutical formulation can improve convenience of medication by effectively masking the bitter taste of the drug and the irritation during swallowing, can provide the oxidation stability of varenicline and can improve the solubility of the drug.

Abstract: The present invention provides a pharmaceutical formulation comprising clomipramine or its pharmaceutically acceptable salt (preferably, clomipramine hydrochloride) as the first active ingredient, and sildenafil or its pharmaceutically acceptable salt (preferably, sildenafil citrate) as the second active ingredient, wherein stability of clomipramine is improved, and a method for manufacturing this pharmaceutical formulation. In particular, the present invention provides a pharmaceutical formulation comprising the above two active ingredients and manufactured by using a wet granulation method, wherein stability of clomipramine is improved, and a method for manufacturing this pharmaceutical formulation.

Abstract: The present invention relates to a pharmaceutical composition for treating, preventing or improving premature ejaculation, which is taken on demand prior to sexual activity, the composition comprising clomipramine hydrochloride in an amount of 14 to 16 mg, preferably about 15 mg, as an active ingredient. More preferably, the composition of the present invention further comprises pregelatinized starch and sodium starch glycolate. The pharmaceutical composition of the present invention can provide rapid onset of efficacy, reduce a dissolution (absorption) deviation according to the patient's gastrointestinal pH conditions and minimize side effects.

Abstract: The present invention relates to a pharmaceutical preparation for oral administration comprising, as an active ingredient, clomipramine or a pharmaceutically acceptable salt thereof; and a cation exchange resin and an anion polymer as a taste masking agent, wherein the pharmaceutical preparation can be orally administered even while comprising a pharmaceutically effective amount of clomipramine because the unique tastes of clomipramine, particularly, all of the bitter taste, spicy taste and burning taste are effectively masked, and thus the convenience of drug intake and portability is improved, and a method for manufacturing thereof.

Abstract: The present invention relates to a purgative composition containing polyethylene glycol and sodium picosulfate, wherein the stability of sodium picosulfate is improved by adding a pH controller. According to the present invention, the purgative composition ensures the stability of medicinal ingredients and has a great advantage of having a small dose even while showing a bowel cleansing rate greater than or equal to a commercial preparation, which should be taken in a large dose. In addition, according to the present invention, the composition has high compliance due to a good taste.

Abstract: The present invention relates to a purgative composition for cleansing an intestinal tract and, specifically, to a purgative composition for cleansing an intestinal tract, the composition containing 40-60 g of polyethylene glycol, 10-28 g of sorbitol, and 1-10 mg of sodium picosulfate, on the basis of 100 ml of the composition, or 40-60 g of polyethylene glycol, 10-28 g of sorbitol, and 1-15 mg of bisacodyl, on the basis of 100 ml of the composition. The purgative composition according to the present invention has higher drug compliance while showing an excellent intestinal tract cleansing rate. In addition, the purgative composition exhibits a sufficient intestinal tract cleansing effect even when taken together with a small amount of water, thereby relieving the suffering that a patient must take a large amount of medicine when taking a purgative.

Abstract: The present invention provides a pharmaceutical formulation comprising clomipramine or its pharmaceutically acceptable salt (preferably, clomipramine hydrochloride) as the first active ingredient, and sildenafil or its pharmaceutically acceptable salt (preferably, sildenafil citrate) as the second active ingredient, wherein stability of clomipramine is improved, and a method for manufacturing this pharmaceutical formulation. In particular, the present invention provides a pharmaceutical formulation comprising the above two active ingredients and manufactured by using a wet granulation method, wherein stability of clomipramine is improved, and a method for manufacturing this pharmaceutical formulation.

Abstract: The present invention provides a pharmaceutical formulation comprising clomipramine or its pharmaceutically acceptable salt (preferably, clomipramine hydrochloride) as the first active ingredient, and sildenafil or its pharmaceutically acceptable salt (preferably, sildenafil citrate) as the second active ingredient, wherein stability of clomipramine is improved, and a method for manufacturing this pharmaceutical formulation. In particular, the present invention provides a pharmaceutical formulation comprising the above two active ingredients and manufactured by using a wet granulation method, wherein stability of clomipramine is improved, and a method for manufacturing this pharmaceutical formulation.

Abstract: The present invention relates to a pharmaceutical preparation comprising entecavir as an active ingredient, wherein an antioxidizing agent is added to enhance stability of entecavir, and a method for preparing the same. According to the present invention, the invention has an effect that entecavir can be stably maintained in a pharmaceutical preparation containing a certain amount or more of moisture by adding the antioxidizing agent, thereby a pharmaceutical preparation can be provided as a formulation containing a certain amount or more of moisture, for example, an orally disintegrating film formulation.

Abstract: The present invention relates to a novel Lactobacillus brevis G-101 strain capable of decomposing monosodium L-glutamate (MSG), and a functional health food, a pharmaceutical composition, or a food product comprising the same as an active ingredient. More specifically, the strain is effective in reducing in vivo blood MSG levels of animals and attenuating MSG Symptom Complex, and thus can be used in a functional health food, a pharmaceutical composition, or a food product aiming to prevent in vivo absorption of MSG, which is known to be harmful, and improve the MSG Symptom Complex.

Abstract: The present invention provides a method for preparing a film comprising a high amount of a sildenafil free base uniformly dispersed therein and having a suitable thickness and size, as well as flexibility providing good handling stability and being not prone to breaking. The present invention also provides a sildenafil free base-containing film prepared from the method.

Abstract: The present invention relates to a pharmaceutical preparation for oral administration comprising, as an active ingredient, clomipramine or a pharmaceutically acceptable salt thereof; and a cation exchange resin and an anion polymer as a taste masking agent, wherein the pharmaceutical preparation can be orally administered even while comprising a pharmaceutically effective amount of clomipramine because the unique tastes of clomipramine, particularly, all of the bitter taste, spicy taste and burning taste are effectively masked, and thus the convenience of drug intake and portability is improved, and a method for manufacturing thereof.